Statera Biopharma, Inc. (STAB)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 21, 2025, 3:00 PM EST
Statera Biopharma Revenue
Statera Biopharma had revenue of $670.47K in the quarter ending September 30, 2022, with 183.48% growth. This brings the company's revenue in the last twelve months to $3.69M, up 1,459.14% year-over-year. In the year 2021, Statera Biopharma had annual revenue of $1.49M.
Revenue (ttm)
3.69M
Revenue Growth
+1,459.14%
P/S Ratio
0.00
Revenue / Employee
80.17K
Employees
46
Market Cap
7.26K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2021 | 1.49M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionStatera Biopharma News
- 2 years ago - Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs - GlobeNewsWire
- 2 years ago - Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace - Accesswire
- 2 years ago - Statera Biopharma Receives Positive Nasdaq Listing Determination - Accesswire
- 2 years ago - Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF - Accesswire
- 2 years ago - Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients - Accesswire
- 2 years ago - Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K - Accesswire
- 2 years ago - Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency - Accesswire
- 2 years ago - Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq - Accesswire